PBT-3, a hepoxilin stable analog, causes long term inhibition of growth of K562 solid tumours in vivo.
We demonstrate herein that daily administration of PBT-3 for 8 days to NU/NU mice bearing solid tumours derived from the s.c. administration of the leukemic cell line K562 results in inhibition of growth of the tumours in vivo, and this inhibition lasts for 60 days after stopping treatment with PBT-3 before recovery of tumour growth is re-established. Similar findings were observed when the mice were treated with Gleevec (STI-571). These results provide new evidence that PBT-3 is effective in controlling solid tumour growth in vivo and suggest that the PBT family may be useful in the development of new drugs in cancer therapy.
Li
Xiang
X
Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, Canada M5G 1X8.
Qiao
Na
N
Reynaud
Denis
D
Abdelhaleem
Mohamed
M
Pace-Asciak
Cecil R
CR
D015126:8,11,14-Eicosatrienoic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D005260:Female; D006131:Growth Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D020014:K562 Cells; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation
D000970:Antineoplastic Agents; D006131:Growth Inhibitors; C453725:PBT-3 compound; D015126:8,11,14-Eicosatrienoic Acid